Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028807 | 0.83 | TAAR1 (0.34) | CTSSCTSKCTSL | |
| SCHEMBL29953703 | 0.83 | TAAR1 (0.34) | CTSSCTSKCTSL | |
| SCHEMBL27073675 | 0.81 | P2RX7 (0.36) | P2RX7HTTHPGD | |
| SCHEMBL4846068 | 0.80 | CTSL (0.37) | CTSSCTSKCTSLP2RX7 | |
| SCHEMBL29951564 | 0.80 | P2RX7 (0.35) | CTSSCTSKCTSLP2RX7HTT | |
| SCHEMBL14220184 | 0.79 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL586106 | 0.79 | CTSL (0.33) | CTSSCTSKCTSL | |
| SCHEMBL27828875 | 0.77 | CTSS (0.40) | CTSSCTSKCTSLHTTHPGD | |
| SCHEMBL12844610 | 0.75 | CTSL (0.40) | CTSSCTSKCTSLP2RX7HTT | |
| SCHEMBL2544154 | 0.75 | CTSS (0.45) | CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8398887-B2 | Liquid crystal compounds of butylenes | YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) | 2013-03-19 | — | — | US | disclosed |
| US-20110260106-A1 | LIQUID CRYSTAL COMPOUNDS OF BUTYLENES | VALIANT CORPORATION LIMITED (CN) | 2011-10-27 | — | — | US | disclosed |
| EP-2013209-B1 | PYRAZOLO-TETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7834028-B2 | insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-11-16 | — | — | US | disclosed |
| US-7834028-B2 | insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-16 | — | — | US | disclosed |
| WO-2007122591-A2 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CTSS 2647/4885CTSK 1230/4885CTSL 2478/4885 |
| US-20110260106-A1 | LIQUID CRYSTAL COMPOUNDS OF BUTYLENES | OR10J3, CNOT1, MYB | CTSS 4348/4885CTSK 3060/4885CTSL 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.